Clinical Trials Browser

Advanced Solid Tumors × pembrolizumab × Clear all

NCT06480552 2026-04-21

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT05083481 2026-04-08

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT05067283 2026-02-12

KANDLELIT-001

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT07215637 2026-02-02

Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT07231458 2026-01-16

A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 1 Active not recruiting

Other solid neoplasmSarcoma

Advanced Solid Tumors

NCT06719362 2025-07-10

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT04074759 2025-01-23

FPT155-001

Phase 1 Terminated

80 enrolled 49 charts

Other solid neoplasm

Advanced Solid Tumors

NCT05394350 2024-11-08

MK-1088-002

Phase 1/2 Terminated

27 enrolled 19 charts

Other solid neoplasm

Advanced Solid Tumors

NCT02880371 2022-06-16

A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

Phase 1/2 Terminated

82 enrolled 32 charts

Other solid neoplasm

Advanced Solid Tumors

NCT04699643 2021-01-07

FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

Phase 1/2 Unknown

Other solid neoplasm

Advanced Solid Tumors

NCT02179918 2019-02-08

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)

Phase 1 Completed

23 enrolled 27 charts

Other solid neoplasm

Advanced Solid Tumors